AACR grant recipient Tae Hyun Hwang, PhD, of Vanderbilt University Medical Center, presented his work at the AACR Annual Meeting 2026 on AI agents that work together to assess how patients could respond to therapy and aid doctors in making cancer treatment decisions.
A targeted therapy nearly doubles overall survival in metastatic pancreatic cancer, and the FDA approves a bladder cancer treatment.
At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to discuss targeted cancer prevention.
At the AACR Annual Meeting 2026, researchers discussed the use of vaccines and aspirin to prevent cancer in people with Lynch syndrome.
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and pancreatic cancer, and more.
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
A recent analysis examined whether CYP2D6 metabolism influences tamoxifen response. The answer isn’t entirely clear.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting 2026 enabling new insights into cancer.
An AACR grant to study menin's structure gave researchers the 3D map they needed to produce new treatments for acute myeloid leukemia.
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More